Makoto Hashizume

Makoto Hashizume

Auto-generated profile, based on publicly available information

Makoto Hashizume

Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2002 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MHM. Hashizume
M. Hashizume
MSM. Shimada
M. Shimada
MTM. Tomikawa
M. Tomikawa
YIY. Ikeda
Y. Ikeda
ITI. Takahashi
I. Takahashi
KSK. Sugimachi
K. Sugimachi

1 December 2003 in Surgical Clinics of North America
Verified
Journal Article
Closed access
MHMakoto Hashizume
Makoto Hashizume
KSKeizo Sugimachi
Keizo Sugimachi

27 May 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZYZilong Yan
Zilong Yan
KOKenoki Ohuchida
Kenoki Ohuchida
SFShuang Fei
Shuang Fei
BZBiao Zheng
Biao Zheng
WGWeiyu Guan
Weiyu Guan
MNMasafumi Nakamura
Masafumi Nakamura
Extracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer–stromal interaction. Immunohistochemistry and western blotting were performed to detect the expression of p-ERK1/2 in pancreatic tissues and cells. Cell viability assay was used to study IC50 of ERK inhibitor on pancreatic cancer cells (PCCs) and primary cancer-associated pancreatic stellate cells (PSCs). Transwell migration, invasion, cell viability assay, senescence β-galactosidase staining were performed to determine the effect of ERK inhibitor on PCCs and PSCs in vitro and in vivo. The expression of key factors involved in autophagy and epithelial-to-mesenchymal transition (EMT) process were evaluated by western blotting. The expression of key factors related to cell invasiveness and malignancy were confirmed by qRT-PCR. Co-transplantation of PCC Organoid and PSC using a splenic xenograft mouse model was used to evaluated combined treatment of ERK inhibitor and autophagy inhibitor. Immunohistochemical staining in pancreatic tumor samples and transgenetic mice detected p-ERK1/2 expression in both cancer cells and stromal cells. In pancreatic tissues, p-ERK1/2 was strongly expressed in cancer-associated PSCs compared with cancer cells and normal PSCs. PSCs were also significantly more sensitive to ERK1/2 inhibitor treatment. Inhibition of ERK1/2 suppressed EMT transition in HMPCCs, upregulated cellular senescence markers, activated autophagy in cancer-associated PSCs; and suppressed cancer–stromal interaction, which enhanced invasiveness and viability of cancer cells. We also found that chloroquine, an autophagy inhibitor, suppressed ERK inhibition-induced autophagy and promoted PSC cellular senescence, leading to significantly decreased cell proliferation. The combination of an ERK inhibitor and autophagy inhibitor suppressed liver metastasis in a splenic pancreatic cancer organoid xenograft mouse model. These data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis.

12 February 2013 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
DID. Inoue
D. Inoue
BCB. Cho
B. Cho
MMM. Mori
M. Mori
YKY. Kikkawa
Y. Kikkawa
TAT. Amano
T. Amano
MHM. Hashizume
M. Hashizume
Objective To develop an augmented reality (AR) neuronavigation system with Web cameras and examine its clinical utility. Methods The utility of the system was evaluated in three patients with brain tumors. One patient had a glioblastoma and two patients had convexity meningiomas. Our navigation system comprised the open-source software 3D Slicer (Brigham and Women's Hospital, Boston, Massachusetts, USA), the infrared optical tracking sensor Polaris (Northern Digital Inc., Waterloo, Canada), and Web cameras. We prepared two different types of Web cameras: a handheld type and a headband type. Optical markers were attached to each Web camera. We used this system for skin incision planning before the operation, during craniotomy, and after dural incision. Results We were able to overlay these images in all cases. In Case 1, accuracy could not be evaluated because the tumor was not on the surface, though it was generally suitable for the outline of the external ear and the skin. In Cases 2 and 3, the augmented reality error was ∼2 to 3 mm. Conclusion AR technology was examined with Web cameras in neurosurgical operations. Our results suggest that this technology is clinically useful in neurosurgical procedures, particularly for brain tumors close to the brain surface.

1 May 2014 in Journal of Surgical Research
Verified
Journal Article
Closed access
MUMunenori Uemura
Munenori Uemura
MTMorimasa Tomikawa
Morimasa Tomikawa
RKRyuichi Kumashiro
Ryuichi Kumashiro
TMTiejun Miao
Tiejun Miao
RSRyota Souzaki
Ryota Souzaki
MHMakoto Hashizume
Makoto Hashizume

1 May 2004 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
MHMakoto Hashizume
Makoto Hashizume
KTKouji Tsugawa
Kouji Tsugawa
In the 1990s, laparoscopic surgery entirely changed the traditional style of surgical operations. Laparoscopic cholecystectomy has spread rapidly and is now established as the standard treatment. However, besides cholecystectomy, endoscopic procedures are still not applied so widely to a variety of surgical operations. This is because laparoscopic techniques, such as suturing or ligation, make it difficult for surgeons to perform other kinds of operations and thus greatly increase their mental and physical stress. It is necessary to introduce various advanced technologies such as: surgical robots, three dimensional (3D) images, computer graphics (CG), computer simulation technology and others. Surgical robots, including the AESOP, da Vinci and ZEUS systems, provide surgeons with technologically advanced vision and hand skills. As a result, such systems are expected to revolutionize the field of surgery. However, there have so far been few studies which discuss the indications of robotic surgery for tumors/cancer. Therefore, herein we review various studies published in English to focus on the application of robotic surgery to tumors/cancer. We point out that there are several problems to be solved for robot surgery: i) price of surgical robots, ii) training systems for surgeon, iii) coverage by medical insurance, iv) downsizing and v) navigation system. In conclusion, we believe that, in the near future as robotic technology continues to develop, almost all kinds of endoscopic surgery will be performed by this technology. It will replace traditional surgery not only in the treatment of benign diseases but also in malignant illnesses.